00/12/09 更新

HATORI CLINIC

1133-15,kashimada,saiwaiku,kawasaki  TEL&FAX 044-522-0033

contents
スタチン系薬剤とアルツハイマー病

 

 

診療メモのトップに戻る

ホームに戻る

Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors  
 Author Information  Benjamin Wolozin, MD, PhD; Wendy Kellman; Paul Ruosseau, MD; Gastone G. Celesia, MD; George Siegel, MD

Context  Increasing evidence suggests that cholesterol plays a role in the pathophysiology of Alzheimer disease (AD). For instance, an elevated serum cholesterol level has been shown to be a risk factor for AD.

Objective  To determine whether patients taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which are a group of medicines that inhibit the synthesis of cholesterol, have a lower prevalence of probable AD.

Design  The experiment uses a cross-sectional analysis comparing the prevalence of probable AD in 3 groups of patients from hospital records: the entire population, patients receiving 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (hereafter referred to as the statins), and patients receiving medications used to treat hypertension or cardiovascular disease.

Patients  The subjects studied were those included in the computer databases of 3 different hospitals for the years October 1, 1996, through August 31, 1998.Main Outcome Measures  Diagnosis of probable AD.Results  We find that the prevalence of probable AD in the cohort taking statins during the study interval is 60% to 73% (P<.001) lower than the total patient population or compared with patients taking other medications typically used in the treatment of hypertension or cardiovascular disease.Conclusions  There is a lower prevalence of diagnosed probable AD in patients taking 2 different 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorslovastatin and pravastatin. While one cannot infer causative mechanisms based on these data, this study reveals an interesting association in the data, which warrants further study.

Arch Neurol. 2000;57:1439-1443

(医)はとりクリニック  

 

 

 

高コレステロールの治療薬・スタチン系薬剤

メバロチン、リポバス、ローコール、セルタ、リピトールなど)にアルツハイマー病予防の可能性あり

 

 3-ヒドロキシ-3-メチルグルタリルCoA還元酵素阻害薬、いわゆるスタチン系薬剤に、アルツハイマー病を予防する可能性があるようだ。米国のBenjamin Wolozin氏らが、6万人強の心血管疾患入院患者を追跡調査し明らかにした。 調査の結果、スタチン系薬剤を服薬していた患者のアルツハイマー病発症率は、患者全体、または他の心血管疾患治療薬を服用していた患者に比べ、最大約6割(P0.001)にとどまったという。 これまでの研究で、血清コレステロール値が高いことは、アルツハイマー病の危険因子である可能性が示唆されている。今回の研究結果は、コレステロールがアルツハイマー病の発症に関与する可能性を示す、もう一つの証拠と言えそうだ。

®